Artur V Cideciyan Selected Research

Blindness (Hysterical Blindness)

1/2020	Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy.
1/2017	Postretinal Structure and Function in Severe Congenital Photoreceptor Blindness Caused by Mutations in the GUCY2D Gene.
1/2017	Towards Treatment of Stargardt Disease: Workshop Organized and Sponsored by the Foundation Fighting Blindness.
10/2016	Overlap of abnormal photoreceptor development and progressive degeneration in Leber congenital amaurosis caused by NPHP5 mutation.
5/2015	Improvement and decline in vision with gene therapy in childhood blindness.
2/2013	Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement.
2/2012	Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa.
4/2011	Cone photoreceptors are the main targets for gene therapy of NPHP5 (IQCB1) or NPHP6 (CEP290) blindness: generation of an all-cone Nphp6 hypomorph mouse that mimics the human retinal ciliopathy.
12/2010	Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel.
9/2008	Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Artur V Cideciyan Research Topics

Disease

28	Leber Congenital Amaurosis 01/2022 - 04/2004
24	Retinitis Pigmentosa (Pigmentary Retinopathy) 01/2021 - 04/2002
21	Retinal Degeneration 01/2019 - 04/2002
18	Blindness (Hysterical Blindness) 01/2020 - 04/2002
6	Ciliopathies 01/2021 - 04/2011
6	Retinal Diseases 01/2020 - 02/2004
5	Blue cone monochromatism 01/2022 - 12/2013
5	Stargardt Disease 10/2021 - 03/2004
4	Macular Degeneration (Age-Related Maculopathy) 01/2017 - 07/2002
3	Atrophy 01/2020 - 05/2015
3	Cone-Rod Dystrophies 01/2019 - 06/2002
3	Disease Progression 07/2017 - 05/2009
3	Choroideremia 01/2016 - 03/2002
3	Vision Disorders (Hemeralopia) 12/2013 - 04/2004
2	Low Vision (Subnormal Vision) 01/2022 - 01/2016
2	Photophobia (Light Sensitivity) 01/2021 - 01/2017
2	Scotoma (Scintillating Scotoma) 01/2017 - 04/2008
2	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2017 - 04/2005
2	Usher Syndromes (Usher Syndrome) 01/2016 - 06/2008
2	Laminopathies 03/2014 - 04/2008
2	Enhanced S-Cone Syndrome 03/2003 - 01/2002
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2021
1	Toxic Optic Neuropathy 01/2020
1	Agenesis of Cerebellar Vermis 11/2017
1	Geographic Atrophy 04/2015
1	type 1 Amaurosis congenita of Leber 01/2013
1	Type Ib Usher Syndrome 10/2011
1	type 1B Usher syndrome 04/2009
1	Bardet-Biedl Syndrome (Syndrome, Bardet-Biedl) 11/2006
1	Hypertrophy 09/2006
1	Retinal Perforations 08/2006
1	Choroidal Neovascularization 04/2005
1	Macular Edema 04/2005
1	Late-Onset Retinal Degeneration 10/2003
1	Vitelliform Macular Dystrophy 02/2003
1	Dog Diseases (Disease, Canine) 04/2002

Drug/Important Bio-Agent (IBA)

56	Retinaldehyde (Retinal)IBA 01/2022 - 01/2002
12	Proteins (Proteins, Gene)FDA Link 01/2019 - 09/2006
7	GTP Phosphohydrolases (GTPases)IBA 01/2021 - 05/2007
7	RetinoidsIBA 01/2017 - 04/2005
6	Rhodopsin (Visual Purple)IBA 10/2019 - 04/2002
3	Antisense OligonucleotidesIBA 01/2022 - 01/2019
2	Guanylate Cyclase (Guanylyl Cyclase)IBA 01/2019 - 01/2013
2	Myosins (Myosin)IBA 01/2016 - 10/2011
2	guanylate cyclase 1IBA 08/2015 - 06/2006
2	LipofuscinIBA 06/2015 - 05/2015
2	retinoid isomerohydrolase (retinol isomerase)IBA 06/2009 - 09/2007
2	LuteinIBA 03/2007 - 03/2002
2	Macular PigmentIBA 03/2007 - 03/2002
1	Protein Isoforms (Isoforms)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	N- (4- azidobenzoylglycyl)- S- (2- thiopyridyl)cysteine (AGTC)IBA 01/2020
1	Codon (Codons)IBA 01/2020
1	CalciumIBA 01/2019
1	Adenosine Triphosphate (ATP)IBA 01/2017
1	hydroxide ionIBA 01/2017
1	Retinal Pigments (Pigments, Visual)IBA 01/2017
1	Complement System Proteins (Complement)IBA 01/2016
1	Cone OpsinsIBA 01/2015
1	WD repeat containing planar cell polarity effectorIBA 04/2012
1	Phosphotransferases (Kinase)IBA 12/2011
1	OpsinsIBA 03/2011
1	dehydrodolichyl diphosphate synthetaseIBA 02/2011
1	IsomerasesIBA 12/2010
1	lecithin-retinol acyltransferaseIBA 06/2009
1	DNA (Deoxyribonucleic Acid)IBA 07/2008
1	Melanins (Melanin)IBA 04/2008
1	Complementary DNA (cDNA)IBA 04/2005
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2005
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 03/2004
1	CollagenIBA 10/2003
1	G-Protein-Coupled Receptor Kinase 1 (G Protein-Coupled Receptor Kinase 1)IBA 03/2003
1	Chloride Channels (Chloride Channel)IBA 02/2003
1	Ataxin-7IBA 06/2002
1	Transcription Factors (Transcription Factor)IBA 06/2002

Therapy/Procedure

19	Therapeutics 02/2021 - 02/2005
2	Visual Prosthesis 10/2016 - 04/2012
1	Precision Medicine 01/2020
1	Intravitreal Injections 01/2019
1	Injections 08/2006